DE50012021D1 - Nucleinsauremoleküle mit spezifischer erkennung von nativem prpsc, herstellung und verwendung - Google Patents
Nucleinsauremoleküle mit spezifischer erkennung von nativem prpsc, herstellung und verwendungInfo
- Publication number
- DE50012021D1 DE50012021D1 DE50012021T DE50012021T DE50012021D1 DE 50012021 D1 DE50012021 D1 DE 50012021D1 DE 50012021 T DE50012021 T DE 50012021T DE 50012021 T DE50012021 T DE 50012021T DE 50012021 D1 DE50012021 D1 DE 50012021D1
- Authority
- DE
- Germany
- Prior art keywords
- sup
- molecules
- nucleic acid
- nuclein
- sea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/13—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultrasonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE50012021T DE50012021D1 (de) | 1999-06-01 | 2000-05-31 | Nucleinsauremoleküle mit spezifischer erkennung von nativem prpsc, herstellung und verwendung |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19925073A DE19925073C2 (de) | 1999-06-01 | 1999-06-01 | Nucleinsäuremoleküle mit spezifischer Erkennung von nativem PrP·S··c·, Herstellung und Verwendung |
PCT/EP2000/005020 WO2000073501A2 (de) | 1999-06-01 | 2000-05-31 | Nucleinsäuremoleküle mit spezifischer erkennung von nativem prpsc, herstellung und verwendung |
DE50012021T DE50012021D1 (de) | 1999-06-01 | 2000-05-31 | Nucleinsauremoleküle mit spezifischer erkennung von nativem prpsc, herstellung und verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
DE50012021D1 true DE50012021D1 (de) | 2006-03-30 |
Family
ID=7909872
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19925073A Expired - Fee Related DE19925073C2 (de) | 1999-06-01 | 1999-06-01 | Nucleinsäuremoleküle mit spezifischer Erkennung von nativem PrP·S··c·, Herstellung und Verwendung |
DE50012021T Expired - Fee Related DE50012021D1 (de) | 1999-06-01 | 2000-05-31 | Nucleinsauremoleküle mit spezifischer erkennung von nativem prpsc, herstellung und verwendung |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19925073A Expired - Fee Related DE19925073C2 (de) | 1999-06-01 | 1999-06-01 | Nucleinsäuremoleküle mit spezifischer Erkennung von nativem PrP·S··c·, Herstellung und Verwendung |
Country Status (8)
Country | Link |
---|---|
US (1) | US7371833B1 (de) |
EP (1) | EP1100958B1 (de) |
JP (1) | JP2003501050A (de) |
AT (1) | ATE315105T1 (de) |
AU (1) | AU5527700A (de) |
CA (1) | CA2339131A1 (de) |
DE (2) | DE19925073C2 (de) |
WO (1) | WO2000073501A2 (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000713A1 (en) * | 2000-06-26 | 2002-01-03 | Universität Zürich | Prion-binding activity in serum and plasma determined as plasminogen and fibrinogen |
GB0012054D0 (en) * | 2000-05-18 | 2000-07-12 | Isis Innovation | Ligands |
EP1333090A1 (de) * | 2002-02-01 | 2003-08-06 | NascaCell GmbH | Prionprotein-spezifische Aptamere |
CN101123993A (zh) * | 2002-08-07 | 2008-02-13 | 特拉华大学 | 治疗表现出蛋白质错误组装和聚集的疾病的组合物和方法 |
US7480382B2 (en) * | 2003-09-30 | 2009-01-20 | Microsoft Corporation | Image file container |
CN103301475B (zh) | 2005-12-28 | 2016-08-03 | 斯克里普斯研究所 | 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用 |
CA2739464C (en) * | 2008-10-03 | 2020-03-31 | Opko Curna, Llc | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
MX2011005910A (es) | 2008-12-04 | 2011-06-17 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina. |
US20110294870A1 (en) | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
CA2746003C (en) | 2008-12-04 | 2020-03-31 | Opko Curna, Llc | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
KR101682735B1 (ko) | 2009-02-12 | 2016-12-06 | 큐알엔에이, 인크. | 뇌 유래된 신경영양성 인자 (bdnf)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (bdnf) 관련된 질환의 치료 |
WO2010107733A2 (en) | 2009-03-16 | 2010-09-23 | Curna, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
CN102549159B (zh) | 2009-03-17 | 2016-08-10 | 库尔纳公司 | 通过抑制针对δ样1同源物(DLK1)的天然反义转录物来治疗DLK1相关的疾病 |
KR101835889B1 (ko) | 2009-05-06 | 2018-03-08 | 큐알엔에이, 인크. | 지질 수송 및 대사 유전자에 대한 천연 안티센스 전사체의 억제에 의해 지질 수송 및 대사 유전자 관련된 질환의 치료 |
CA2761142C (en) | 2009-05-06 | 2021-06-08 | Opko Curna, Llc | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
US9012139B2 (en) | 2009-05-08 | 2015-04-21 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family |
DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
WO2010135695A2 (en) | 2009-05-22 | 2010-11-25 | Curna, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
CN103221541B (zh) | 2009-05-28 | 2017-03-01 | 库尔纳公司 | 通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病 |
ES2629339T3 (es) | 2009-06-16 | 2017-08-08 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1 |
JP5944311B2 (ja) | 2009-06-16 | 2016-07-05 | クルナ・インコーポレーテッド | コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療 |
CA2765889A1 (en) | 2009-06-24 | 2010-12-29 | Opko Curna, Llc | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
KR101807324B1 (ko) | 2009-06-26 | 2017-12-08 | 큐알엔에이, 인크. | 다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료 |
CA2768947C (en) | 2009-07-24 | 2018-06-19 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
WO2011017516A2 (en) | 2009-08-05 | 2011-02-10 | Curna, Inc. | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
EP2464731B1 (de) | 2009-08-11 | 2016-10-05 | CuRNA, Inc. | Behandlung von adiponectin (adipoq)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein adiponectin (adipoq) |
EP2982755B1 (de) | 2009-08-21 | 2020-10-07 | CuRNA, Inc. | Behandlung von erkrankungen im zusammenhang mit c-terminus des hsp70-interagierenden proteins (chip) durch hemmung des natürlichen antisense-transkripts gegen chip |
EP2470657B1 (de) | 2009-08-25 | 2019-10-23 | CuRNA, Inc. | Behandlung von iqgap ('iq-motiv-haltiges gtpase-aktivierendes protein')-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen iqgap |
DK2480669T3 (en) | 2009-09-25 | 2018-02-12 | Curna Inc | TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY |
CA2782366A1 (en) | 2009-12-16 | 2011-07-14 | Opko Curna, Llc | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
WO2011079261A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
RU2611186C2 (ru) | 2009-12-29 | 2017-02-21 | Курна, Инк. | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63 |
EP2519633B1 (de) | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Behandlung von erkrankungen im zusammenhang mit dem nuclear-respirator-faktor 1 (nrf1) mittels hemmung des natürlichen antisense-transkripts gegen nrf1 |
RU2016115782A (ru) | 2009-12-31 | 2018-11-28 | Курна, Инк. | Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 и транскрипционному фактору е3 (tfe3) |
US8946181B2 (en) | 2010-01-04 | 2015-02-03 | Curna, Inc. | Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8 |
WO2011085066A2 (en) | 2010-01-06 | 2011-07-14 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
EP2524039B1 (de) | 2010-01-11 | 2017-11-29 | CuRNA, Inc. | Behandlung von krankheiten im zusammenhang mit dem sexualhormonbindenden globulin (shgb) mittels hemmung des natürlichen antisense-transkripts gegen shbg |
RU2611192C2 (ru) | 2010-01-25 | 2017-02-21 | Курна, Инк. | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1 |
KR101838308B1 (ko) | 2010-02-22 | 2018-03-13 | 큐알엔에이, 인크. | 피롤린-5-카르복실레이트 환원효소 1(pycr1)에 대한 천연 안티센스 전사체의 억제에 의한 pycr1과 관련된 질환의 치료 |
US8980856B2 (en) | 2010-04-02 | 2015-03-17 | Curna, Inc. | Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3 |
RU2610661C2 (ru) | 2010-04-09 | 2017-02-14 | Курна, Инк. | Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21 |
RU2693462C2 (ru) | 2010-05-03 | 2019-07-03 | Курна, Инк. | Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt) |
TWI586356B (zh) | 2010-05-14 | 2017-06-11 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
EP2576783B1 (de) | 2010-05-26 | 2017-11-29 | CuRNA, Inc. | Behandlung von durch atonal homolog 1 (atoh1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für atoh1 |
JP5917497B2 (ja) | 2010-05-26 | 2016-05-18 | カッパーアールエヌエー,インコーポレイテッド | メチオニンスルホキシドレダクターゼa(msra)に対する天然アンチセンス転写物の阻害によるmsra関連疾患の治療 |
JP6023705B2 (ja) | 2010-06-23 | 2016-11-09 | カッパーアールエヌエー,インコーポレイテッド | ナトリウムチャネル、電位依存性、αサブユニット(SCNA)に対する天然アンチセンス転写物の阻害によるSCNA関連疾患の治療 |
JP5998131B2 (ja) | 2010-07-14 | 2016-09-28 | カッパーアールエヌエー,インコーポレイテッド | Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療 |
ES2640755T3 (es) | 2010-10-06 | 2017-11-06 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4 |
EP2630241B1 (de) | 2010-10-22 | 2018-10-17 | CuRNA, Inc. | Behandlung von alpha-l-iduronidase (idua)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen idua |
US8987225B2 (en) | 2010-11-23 | 2015-03-24 | Curna, Inc. | Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG |
ES2653247T3 (es) | 2011-06-09 | 2018-02-06 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN |
CN108272782B (zh) | 2011-09-06 | 2021-04-23 | 库尔纳公司 | 小分子在制备治疗Dravet综合征或全面性癫痫伴热性惊厥附加症的药物中的用途 |
US20150031750A1 (en) | 2012-03-15 | 2015-01-29 | The Scripps Research Institute | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
EP3056901B1 (de) | 2015-02-13 | 2018-08-29 | Technische Universität Berlin | Verfahren zum Nachweis von Proteinen mit Hilfe von Aptameren |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543507A (en) * | 1992-03-05 | 1996-08-06 | Isis Pharmaceuticals, Inc. | Covalently cross-linked oligonucleotides |
ATE171210T1 (de) * | 1992-07-02 | 1998-10-15 | Hybridon Inc | Selbststabilisierte oligonukleotide als therapeutika |
DE852011T1 (de) | 1995-09-14 | 2001-10-11 | Univ California | Für natives prp-sc spezifische antikörper |
DE69618614T2 (de) * | 1995-10-26 | 2002-09-12 | Winnacker Ernst Ludwig | NUKLEINSÄUREMOLEKÜLE MIT DER FÄHIGKEIT ZUR UNTERSCHEIDUNG VON PrPc UND PrPSc-PRIONPROTEIN-ISOFORMEN UND VERFAHREN ZU DEREN HERSTELLUNG |
EP0959877A4 (de) * | 1996-04-10 | 2000-08-23 | Univ California | Korrektur der genetischen fehler mittels chemische begleiter |
ATE221663T1 (de) * | 1996-05-29 | 2002-08-15 | Univ Mcgill | Prionbindende proteine und deren verwendungen |
ES2209108T3 (es) * | 1997-02-06 | 2004-06-16 | Enfer Technology Limited | Ensayo inmunologico para encefalopatias espongiformes. |
JP2002501385A (ja) * | 1997-05-30 | 2002-01-15 | ヴァイス ステファン | 可溶性ラミニン受容体前駆体及びその相互作用を阻止するための方法 |
-
1999
- 1999-06-01 DE DE19925073A patent/DE19925073C2/de not_active Expired - Fee Related
-
2000
- 2000-05-31 AT AT00940297T patent/ATE315105T1/de not_active IP Right Cessation
- 2000-05-31 CA CA002339131A patent/CA2339131A1/en not_active Abandoned
- 2000-05-31 EP EP00940297A patent/EP1100958B1/de not_active Expired - Lifetime
- 2000-05-31 WO PCT/EP2000/005020 patent/WO2000073501A2/de active IP Right Grant
- 2000-05-31 DE DE50012021T patent/DE50012021D1/de not_active Expired - Fee Related
- 2000-05-31 AU AU55277/00A patent/AU5527700A/en not_active Abandoned
- 2000-05-31 JP JP2001500811A patent/JP2003501050A/ja active Pending
- 2000-05-31 US US09/744,934 patent/US7371833B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2000073501A3 (de) | 2001-03-08 |
DE19925073C2 (de) | 2001-07-19 |
JP2003501050A (ja) | 2003-01-14 |
AU5527700A (en) | 2000-12-18 |
EP1100958A2 (de) | 2001-05-23 |
CA2339131A1 (en) | 2000-12-07 |
DE19925073A1 (de) | 2001-03-15 |
ATE315105T1 (de) | 2006-02-15 |
EP1100958B1 (de) | 2006-01-04 |
WO2000073501A2 (de) | 2000-12-07 |
US7371833B1 (en) | 2008-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE50012021D1 (de) | Nucleinsauremoleküle mit spezifischer erkennung von nativem prpsc, herstellung und verwendung | |
Bessen et al. | Non-genetic propagation of strain-specific properties of scrapie prion protein | |
Liang et al. | Chemical synthesis of diubiquitin‐based photoaffinity probes for selectively profiling ubiquitin‐binding proteins | |
Solomon et al. | Light chain-associated amyloid deposits comprised of a novel κ constant domain | |
NO20001052L (no) | 1C, 15N, 2H merkede proteiner for NMR-strukturbestemmelser og deres fremstilling | |
DE60111247D1 (de) | Verfahren für die produktion von peptiden unter verwendung eines in vitro transkription/translation system | |
Sevilla et al. | Development of Monoclonal Antibodies to the Malondialdehyde− Deoxyguanosine Adduct, Pyrimidopurinone1 | |
DE60231651D1 (de) | Proteinreinigungsverfahren | |
DE69714654D1 (de) | Verwendung von einem Metalloporphyrinkonjugat für den Nachweis biologischer Verbindungen | |
SE9803838D0 (sv) | A chromatography method and a column material useful in said method | |
DE69942459D1 (de) | Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung | |
DE69821376D1 (de) | Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht | |
ATE212065T1 (de) | Nukleinsäuremoleküle mit der fähigkeit zur unterscheidung von prpc und prpsc-prionprotein- isoformen und verfahren zu deren herstellung | |
Rosen et al. | Capture and Recycling of Sortase A through Site‐Specific Labeling with Lithocholic Acid | |
Lakemeyer et al. | Tailored peptide phenyl esters block ClpXP proteolysis by an unusual breakdown into a heptamer–hexamer assembly | |
Ramanathan et al. | Modular synthesis of cyclic peptidomimetics inspired by γ-turns | |
Rao et al. | Identification by mass spectrometry of a new α-tubulin isotype expressed in human breast and lung carcinoma cell lines | |
Rae et al. | Lactoperoxidase heme structure characterized by paramagnetic proton NMR spectroscopy | |
Heinnickel et al. | Resolution and reconstitution of a bound Fe− S protein from the photosynthetic reaction center of Heliobacterium modesticaldum | |
Crofton | Site of alkaline phosphatase attachment in alkaline phosphatase-immunoglobulin G complexes | |
ATE369442T1 (de) | In vitro evolution von nukleinsäuren und kodierten polypeptiden | |
DK1540304T3 (da) | Depletering af plasmaproteiner | |
Itakura et al. | Evidence that malondialdehyde-derived aminoenimine is not a fluorescent age pigment | |
Parker et al. | Control of the yeast cell cycle with a photocleavable α-factor analogue | |
Bi et al. | Affinity‐Based Labeling of Cytohesins with a Bifunctional SecinH3 Photoaffinity Probe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |